HROW News and Press, Harrow Health Inc. From 03/02/24

2024-03-02 14:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-21 11:40:00 ET Summary SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated 17.15% during 2023. I believe our holdings present a significant opportunity with minimal fundamental downside and s...

2024-02-19 09:30:00 ET Summary Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheezo, initially faced skepticism but has seen signifi...

2024-02-05 03:26:15 ET Summary Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to their $25 per share liquidation value. Cash and...

2024-01-30 16:03:51 ET Summary Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a decline in revenue. Despite short-term challenges, ...

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company’s Board of Directors, effective immediately. Harrow’s Board now consists of six members. “I am deligh...

2024-01-19 13:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-11 10:34:40 ET More on Harrow Health Despite Q3 Earnings Miss, Harrow Is Still Appealing For 2024 Harrow, Inc. (HROW) Q3 2023 Earnings Call Transcript Implications Of Harrow's Short-Term Guidance Harrow stock tumbles 38% in wake of Q3 report, revised ...

VEVYE® Offers Rapid Onset with Clinically and Statistically Meaningful Improvement Beginning as Early as 15 Days 1 with Sustained Improvement over 56 Weeks 2 VEVYE® Patients to Have Access to a 100% Money-Back Guarantee Program 3 Harrow (Nasdaq: HRO...

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation endpoint in its Phase 2 Pivota...